IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena
- Address
- Via Elio Chianesi 53, Roma, 00144 Rome, Italy
IRCCS Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
The IRCCS Istituto Nazionale Tumori Regina Elena is a leading Italian comprehensive cancer center specializing in advanced oncology research and innovative therapeutic approaches. The institute focuses on precision medicine strategies for complex malignancies, with particular emphasis on targeted therapies, immunotherapy combinations, and PARP inhibitor maintenance strategies.
- Gynecologic oncology, including recurrent and advanced ovarian cancer with BRCA wild-type and PARP inhibitor maintenance beyond progression
- Thoracic malignancies featuring EGFR exon 20 insertion mutations in non-small cell lung cancer and pleural mesothelioma with HRR gene mutations
- Genitourinary cancers, particularly metastatic renal cell carcinoma with novel immunotherapy intensification strategies
- Biomarker-driven treatment selection integrating PD-L1 expression and homologous recombination repair pathway analysis
The center's research portfolio demonstrates expertise in multi-center phase II and III clinical trials evaluating next-generation targeted agents and combination immunotherapy regimens. Their work emphasizes the integration of surgical interventions, including secondary cytoreductive surgery, with novel maintenance therapies and the investigation of treatment sequencing strategies to optimize progression-free survival outcomes in patients with advanced solid tumors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in IRCCS Istituti Fisioterapici Ospitalieri- Istituto Nazionale tumori Regina Elena
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-Type Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | IRCCS Istituto Nazionale Tumori Fondazione Pascale | Phase II | Recruiting | Dec 2024 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2023-09-26 | 2025-01-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.